XL-784

XL-784 is a selective matrix metalloproteinases (MMP) inhibitor, with IC50s of ~1900, 0.81, 120, 10.8, 18, 0.56 nM for MMP-1，MMP-2，MMP-3，MMP-8，MMP-9，MMP-13，respectively.

Product information

CAS Number: 1224964-36-6

Molecular Weight: 561.07

Formula: C42H42Cl2F4MgN6O16S2

Chemical Name: magnesium(2+) bis(({1-[4-(4-chlorophenoxy)-3,5-difluorobenzenesulfonyl]-4-[(2-methoxyethoxy)carbonyl]piperazin-2-yl}formamido)olate)

Smiles: [Mg+2].COCCOC(=O)N1CC(C(=O)N[O-])N(CC1)S(=O)(=O)C1=CC(F)=C(OC2C=CC(Cl)=CC=2)C(F)=C1.COCCOC(=O)N1CC(C(=O)N[O-])N(CC1)S(=O)(=O)C1=CC(F)=C(OC2C=CC(Cl)=CC=2)C(F)=C1

InChiKey: GEMFCHZXWCHUJU-UHFFFAOYSA-N

InChi: InChI=1S/2C21H21ClF2N3O8S.Mg/c2*1-33-8-9-34-21(29)26-6-7-27(18(12-26)20(28)25-30)36(31,32)15-10-16(23)19(17(24)11-15)35-14-4-2-13(22)3-5-14;/h2*2-5,10-11,18H,6-9,12H2,1H3,(H-,25,28,30);/q2*-1;+2

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : ≥ 110 mg/mL (200.39 mM).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

XL-784 is a highly potent, low-molecular-weight (1,122 g/mol) inhibitor of MMPs that has very limited aqueous solubility (20 μg/mL). XL-784 potently inhibits MMP-2, MMP-13, andADAM10 [TNF-α-converting enzyme (TACE)] activity in vitro, with IC50 values in the range of 1-2 nM. XL-784 also inhibits MMP-9 (IC50 ~20 nM) activity and ADAM17 (IC50 ~70 nM) also known as TACE. However, it exhibits low potency for inhibition of MMP-1 (IC50 ~2,000 nM).

In Vivo:

All mice tolerate the treatments similarly. Control mice all developed aneurysms with a mean %△AD of 158.5%±4.3%. Treatment with all doses of XL-784 and doxycycline are effective in inhibiting aortic dilatation. There is a clear dose-response relationship between XL-784 and reductions in aortic dilatation at harvest (50 mg/kg 140.4% ±3.2%; 125 mg/kg 129.3% ±5.1%; 250 mg/kg 119.2%±3.5%; all Ps<0.01 compared to control). This continues with the higher doses (375 mg/kg 88.6%±4.4%; 500 mg/kg 76.0%±3.5%). The highest 2 doses of XL-784 tested are more effective than doxycycline (112.2%±2.0%, P<0.05) in inhibiting maximal dilatation of the aorta after elastase perfusion.

Products are for research use only. Not for human use.